SCF PIPELINE FOR PURIFIED BOTANICAL-DERIVED API (OPTION A)

PROJECT AMMONEX-HE

FDA-Aligned Botanical Drug Development Pathway

Discovery → IND → First-In-Human

Document Code: SCF-AMMONEX-HE-BOTAPI-0001

Development Strategy: Option A — Purified Botanical-Derived API

Primary Botanical Sources:

• Phyllanthus niruri
• Genipa americana
• Croton lechleri
• Scutellaria baicalensis
• Coptis chinensis

EXECUTIVE STRATEGY

Unlike Option B (semi-synthetic NCE development), Option A maintains the active pharmaceutical ingredient as a purified botanical-derived molecule or highly standardized phytochemical fraction.

This strategy seeks to:

• Reduce chemistry development burden
• Leverage existing human exposure history
• Accelerate discovery timelines
• Preserve multi-target pharmacology
• Create FDA-compliant botanical-derived APIs

However, FDA development remains rigorous and requires the same fundamental demonstration of safety, quality, and efficacy necessary for human testing.

STAGE 0

SCF BOTANICAL SOURCE INTELLIGENCE

Trigger

SOURCE SELECT

Objectives

Botanical Authentication

Required:

• Taxonomic confirmation
• DNA barcoding
• Voucher specimen
• Geographic origin documentation

SCF Analysis

Apply:

• Targeted Drug Action
• Pharmacokinetic Optimization
• Metabolic Efficiency
• Resistance Prevention
• Safety Profile

SCF botanical selection framework.

Deliverables

Botanical Source Dossier

Includes:

• Traditional use
• Ethnomedical history
• Known pharmacology
• Safety history
• Cultivation feasibility

STAGE 1

BIOACTIVE EXTRACTION & FRACTIONATION

Trigger

EXTRACT API

Objective

Generate purified bioactive fractions suitable for pharmaceutical development.

Extraction Workflow

Step 1

Raw Material Standardization

Measure:

• Moisture
• Contaminants
• Heavy metals
• Microbial burden

Step 2

Extraction

Methods:

• Ethanol extraction
• Hydroethanolic extraction
• Supercritical CO₂
• Bioaffinity extraction

Selection depends upon target chemistry.

Step 3

Fractionation

Methods:

• Preparative HPLC
• Flash chromatography
• Bioassay-guided fractionation

Step 4

Purification

Target:

≥95% purity for lead API candidate.

Framework follows SCF Extraction of Biological Molecules Protocol.

Deliverables

Purified Botanical API

Examples:

• Geniposide
• Genipin
• Berberine
• Baicalin
• Corilagin

STAGE 2

SCF MoA / MeA CHARACTERIZATION

Trigger

PROFILE API

Objective

Identify pharmacologic mechanism.

Studies

Molecular Docking

Targets:

• Urease
• TLR4
• NF-κB
• CPS1 pathway regulators
• NLRP3

Cell-Based Assays

Measure:

• Ammonia metabolism
• Cytokines
• Barrier integrity
• Astrocyte protection

Deliverables

Mechanistic Dossier

Contains:

• Mode of Action (MoA)
• Mechanism of Action (MeA)
• Target ranking
• Selectivity profile

SCF MoA/MeA workflow.

STAGE 3

HIT-TO-LEAD BOTANICAL OPTIMIZATION

Trigger

OPTIMIZE BOTANICAL

Objective

Select final purified botanical API.

Selection Criteria

Example Candidate Progression

Geniposide

↓ Purification

↓ PK optimization

↓ Formulation optimization

↓

AMX-B01

Botanical API Candidate

STAGE 4

PHARMACEUTICAL DEVELOPMENT

Trigger

BUILD CMC

Objective

Transform purified botanical molecule into a pharmaceutical product.

Required Activities

Analytical Methods

• HPLC
• LC-MS
• NMR
• Impurity profile

Specifications

• Identity
• Potency
• Purity
• Stability

Formulation Development

Potential dosage forms:

• Capsule
• Tablet
• Modified-release capsule

Deliverables

CMC Package

Supports IND filing.

STAGE 5

PRECLINICAL DEVELOPMENT

Trigger

PRECLINICAL BOTANICAL

Pharmacology

In Vitro

• Urease assays
• Hepatocyte assays
• Astrocyte assays
• Gut barrier assays

In Vivo

• Hyperammonemia model
• Portal-systemic shunt model
• Bile duct ligation model

ADME

Required:

• Absorption
• Distribution
• Metabolism
• Excretion

Toxicology

Required:

• Safety pharmacology
• Genotoxicity
• Repeat-dose toxicity

FDA IND-enabling expectations.

STAGE 6

BOTANICAL API DEVELOPMENT CANDIDATE NOMINATION

Trigger

NOMINATE API

Decision Gate

GO Criteria

Example Nomination

AMX-B01

Geniposide-Enriched Purified Botanical API

or

AMX-B02

Berberine-Enriched Purified Botanical API

or

AMX-B03

Corilagin-Enriched Purified Botanical API

STAGE 7

IND PACKAGE DEVELOPMENT

Trigger

BOTANICAL IND

FDA IND Components

Module 3

CMC

• Botanical source controls
• Manufacturing process
• Specifications
• Stability

Module 4

Nonclinical

• Pharmacology
• Toxicology
• ADME

Module 5

Clinical Protocol

• SAD
• MAD
• Biomarkers

FDA IND architecture.

STAGE 8

FIRST-IN-HUMAN

Trigger

BOTANICAL FIH

Study Design

Phase I SAD

Objectives:

• Safety
• Tolerability
• PK

Phase I MAD

Objectives:

• Repeat-dose safety
• Exposure accumulation
• Pharmacodynamic biomarkers

RECOMMENDED BOTANICAL API PRIORITIZATION

For hepatic encephalopathy ammonia modulation, the most development-friendly purified botanical APIs are:

Preferred Initial Program

AMX-B01 (Geniposide Purified Botanical API)

Reason:

• Strong alignment with hepatic nitrogen-metabolism restoration
• Single dominant phytochemical marker
• Easier standardization than complex botanical mixtures
• Clear CMC pathway
• Potentially simpler regulatory development than a multi-component botanical fraction

CHATGPT PIPELINE COMMANDS

MASTER REGISTRY INDEX

SCF-AMMONEX-HE-BOTAPI-0001 — Purified Botanical API Pipeline

SCF-AMMONEX-HE-AMXB01-0002 — Geniposide Development Program

SCF-AMMONEX-HE-AMXB02-0003 — Berberine Development Program

SCF-AMMONEX-HE-AMXB03-0004 — Corilagin Development Program

SCF-AMMONEX-HE-BOTCMC-0005 — Botanical CMC Framework

SCF-AMMONEX-HE-BOTIND-0006 — Botanical IND Strategy

SCF-AMMONEX-HE-BOTFIH-0007 — Botanical First-In-Human Program